174 related articles for article (PubMed ID: 31237791)
1. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment.
Amiri S; Lutz RB; McDonell MG; Roll JM; Amram O
Am J Drug Alcohol Abuse; 2020; 46(1):78-87. PubMed ID: 31237791
[No Abstract] [Full Text] [Related]
2. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O
Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146
[TBL] [Abstract][Full Text] [Related]
3. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.
Amiri S; Lutz R; Socías ME; McDonell MG; Roll JM; Amram O
J Subst Abuse Treat; 2018 Oct; 93():26-30. PubMed ID: 30126538
[TBL] [Abstract][Full Text] [Related]
4. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
5. Quantifying spatial accessibility in public health practice and research: an application to on-premise alcohol outlets, United States, 2013.
Lu H; Zhang X; Holt JB; Kanny D; Croft JB
Int J Health Geogr; 2018 Jun; 17(1):23. PubMed ID: 29945619
[TBL] [Abstract][Full Text] [Related]
6. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives.
Hatch-Maillette MA; Peavy KM; Tsui JI; Banta-Green CJ; Woolworth S; Grekin P
J Subst Abuse Treat; 2021 May; 124():108223. PubMed ID: 33342667
[TBL] [Abstract][Full Text] [Related]
7. Changes in methadone take-home dosing before and after COVID-19.
Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
[TBL] [Abstract][Full Text] [Related]
8. Alcohol Outlets, Neighborhood Retail Environments, and Pedestrian Injury Risk.
Nesoff ED; Milam AJ; Branas CC; Martins SS; Knowlton AR; Furr-Holden DM
Alcohol Clin Exp Res; 2018 Oct; 42(10):1979-1987. PubMed ID: 30102415
[TBL] [Abstract][Full Text] [Related]
9. Distances to on- and off-premise alcohol outlets and experiences of alcohol-related amenity problems.
Wilkinson C; Livingston M
Drug Alcohol Rev; 2012 Jun; 31(4):394-401. PubMed ID: 21919975
[TBL] [Abstract][Full Text] [Related]
10. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
11. Exposure to alcohol outlets, alcohol access, and alcohol consumption among adolescents.
Morrison CN; Byrnes HF; Miller BA; Wiehe SE; Ponicki WR; Wiebe DJ
Drug Alcohol Depend; 2019 Dec; 205():107622. PubMed ID: 31760294
[TBL] [Abstract][Full Text] [Related]
12. Distance traveled and cross-state commuting to opioid treatment programs in the United States.
Rosenblum A; Cleland CM; Fong C; Kayman DJ; Tempalski B; Parrino M
J Environ Public Health; 2011; 2011():948789. PubMed ID: 21776440
[TBL] [Abstract][Full Text] [Related]
13. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP
Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071
[TBL] [Abstract][Full Text] [Related]
14. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
15. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
16. Challenges to Opioid Treatment Programs After Hurricane Sandy: Patient and Provider Perspectives on Preparation, Impact, and Recovery.
Matusow H; Benoit E; Elliott L; Dunlap E; Rosenblum A
Subst Use Misuse; 2018 Jan; 53(2):206-219. PubMed ID: 28296524
[TBL] [Abstract][Full Text] [Related]
17. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
18. Is access to alcohol associated with alcohol/substance abuse among people diagnosed with anxiety/mood disorder?
Pearson AL; Bowie C; Thornton LE
Public Health; 2014 Nov; 128(11):968-76. PubMed ID: 25443109
[TBL] [Abstract][Full Text] [Related]
19. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
